Cargando…
Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013–2019
Background: Prior studies have not clearly established risk of cardiovascular disease (CVD) among smokers who switch to exclusive use of electronic nicotine delivery systems (ENDS). We compared cardiovascular disease incidence in combustible-tobacco users, those who transitioned to ENDS use, and tho...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998731/ https://www.ncbi.nlm.nih.gov/pubmed/35409819 http://dx.doi.org/10.3390/ijerph19074137 |
_version_ | 1784685013496758272 |
---|---|
author | Mahoney, Martin C. Rivard, Cheryl Kimmel, Heather L. Hammad, Hoda T. Sharma, Eva Halenar, Michael J. Sargent, Jim Cummings, K. Michael Niaura, Ray Goniewicz, Maciej L. Bansal-Travers, Maansi Hatsukami, Dorothy Gaalema, Diann Fong, Geoffrey Gravely, Shannon Christensen, Carol H. Haskins, Ryan Silveira, Marushka L. Blanco, Carlos Compton, Wilson Stanton, Cassandra A. Hyland, Andrew |
author_facet | Mahoney, Martin C. Rivard, Cheryl Kimmel, Heather L. Hammad, Hoda T. Sharma, Eva Halenar, Michael J. Sargent, Jim Cummings, K. Michael Niaura, Ray Goniewicz, Maciej L. Bansal-Travers, Maansi Hatsukami, Dorothy Gaalema, Diann Fong, Geoffrey Gravely, Shannon Christensen, Carol H. Haskins, Ryan Silveira, Marushka L. Blanco, Carlos Compton, Wilson Stanton, Cassandra A. Hyland, Andrew |
author_sort | Mahoney, Martin C. |
collection | PubMed |
description | Background: Prior studies have not clearly established risk of cardiovascular disease (CVD) among smokers who switch to exclusive use of electronic nicotine delivery systems (ENDS). We compared cardiovascular disease incidence in combustible-tobacco users, those who transitioned to ENDS use, and those who quit tobacco with never tobacco users. Methods: This prospective cohort study analyzes five waves of Population Assessment of Tobacco and Health (PATH) Study data, Wave 1 (2013–2014) through Wave 5 (2018–2019). Cardiovascular disease (CVD) incidence was captured over three intervals (Waves 1 to 3, Waves 2 to 4, and Waves 3 to 5). Participants were adults (40+ years old) without a history of CVD for the first two waves of any interval. Change in tobacco use status, from exclusive past 30 day use of any combustible-tobacco product to either exclusive past 30 day ENDS use, dual past 30 day use of ENDS and combustible-tobacco, or no past 30 day use of any tobacco, between the first two waves of an interval was used to predict onset of CVD between the second and third waves in the interval. CVD incidence was defined as a new self-report of being told by a health professional that they had congestive heart failure, stroke, or a myocardial infarction. Generalized estimating equation (GEE) analyses combined 10,548 observations across intervals from 7820 eligible respondents. Results: Overall, there were 191 observations of CVD among 10,548 total observations (1.7%, standard error (SE) = 0.2), with 40 among 3014 never users of tobacco (1.5%, SE = 0.3). In multivariable models, CVD incidence was not significantly different for any tobacco user groups compared to never users. There were 126 observations of CVD among 6263 continuing exclusive combustible-tobacco users (adjusted odds ratio [AOR] = 1.44; 95% confidence interval (CI) 0.87–2.39), 15 observations of CVD among 565 who transitioned to dual use (AOR = 1.85; 0.78–4.37), and 10 observations of CVD among 654 who quit using tobacco (AOR = 1.18; 0.33–4.26). There were no observations of CVD among 53 who transitioned to exclusive ENDS use. Conclusions: This study found no difference in CVD incidence by tobacco status over three 3 year intervals, even for tobacco quitters. It is possible that additional waves of PATH Study data, combined with information from other large longitudinal cohorts with careful tracking of ENDS use patterns may help to further clarify this relationship. |
format | Online Article Text |
id | pubmed-8998731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89987312022-04-12 Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013–2019 Mahoney, Martin C. Rivard, Cheryl Kimmel, Heather L. Hammad, Hoda T. Sharma, Eva Halenar, Michael J. Sargent, Jim Cummings, K. Michael Niaura, Ray Goniewicz, Maciej L. Bansal-Travers, Maansi Hatsukami, Dorothy Gaalema, Diann Fong, Geoffrey Gravely, Shannon Christensen, Carol H. Haskins, Ryan Silveira, Marushka L. Blanco, Carlos Compton, Wilson Stanton, Cassandra A. Hyland, Andrew Int J Environ Res Public Health Article Background: Prior studies have not clearly established risk of cardiovascular disease (CVD) among smokers who switch to exclusive use of electronic nicotine delivery systems (ENDS). We compared cardiovascular disease incidence in combustible-tobacco users, those who transitioned to ENDS use, and those who quit tobacco with never tobacco users. Methods: This prospective cohort study analyzes five waves of Population Assessment of Tobacco and Health (PATH) Study data, Wave 1 (2013–2014) through Wave 5 (2018–2019). Cardiovascular disease (CVD) incidence was captured over three intervals (Waves 1 to 3, Waves 2 to 4, and Waves 3 to 5). Participants were adults (40+ years old) without a history of CVD for the first two waves of any interval. Change in tobacco use status, from exclusive past 30 day use of any combustible-tobacco product to either exclusive past 30 day ENDS use, dual past 30 day use of ENDS and combustible-tobacco, or no past 30 day use of any tobacco, between the first two waves of an interval was used to predict onset of CVD between the second and third waves in the interval. CVD incidence was defined as a new self-report of being told by a health professional that they had congestive heart failure, stroke, or a myocardial infarction. Generalized estimating equation (GEE) analyses combined 10,548 observations across intervals from 7820 eligible respondents. Results: Overall, there were 191 observations of CVD among 10,548 total observations (1.7%, standard error (SE) = 0.2), with 40 among 3014 never users of tobacco (1.5%, SE = 0.3). In multivariable models, CVD incidence was not significantly different for any tobacco user groups compared to never users. There were 126 observations of CVD among 6263 continuing exclusive combustible-tobacco users (adjusted odds ratio [AOR] = 1.44; 95% confidence interval (CI) 0.87–2.39), 15 observations of CVD among 565 who transitioned to dual use (AOR = 1.85; 0.78–4.37), and 10 observations of CVD among 654 who quit using tobacco (AOR = 1.18; 0.33–4.26). There were no observations of CVD among 53 who transitioned to exclusive ENDS use. Conclusions: This study found no difference in CVD incidence by tobacco status over three 3 year intervals, even for tobacco quitters. It is possible that additional waves of PATH Study data, combined with information from other large longitudinal cohorts with careful tracking of ENDS use patterns may help to further clarify this relationship. MDPI 2022-03-31 /pmc/articles/PMC8998731/ /pubmed/35409819 http://dx.doi.org/10.3390/ijerph19074137 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mahoney, Martin C. Rivard, Cheryl Kimmel, Heather L. Hammad, Hoda T. Sharma, Eva Halenar, Michael J. Sargent, Jim Cummings, K. Michael Niaura, Ray Goniewicz, Maciej L. Bansal-Travers, Maansi Hatsukami, Dorothy Gaalema, Diann Fong, Geoffrey Gravely, Shannon Christensen, Carol H. Haskins, Ryan Silveira, Marushka L. Blanco, Carlos Compton, Wilson Stanton, Cassandra A. Hyland, Andrew Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013–2019 |
title | Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013–2019 |
title_full | Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013–2019 |
title_fullStr | Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013–2019 |
title_full_unstemmed | Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013–2019 |
title_short | Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013–2019 |
title_sort | cardiovascular outcomes among combustible-tobacco and electronic nicotine delivery system (ends) users in waves 1 through 5 of the population assessment of tobacco and health (path) study, 2013–2019 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998731/ https://www.ncbi.nlm.nih.gov/pubmed/35409819 http://dx.doi.org/10.3390/ijerph19074137 |
work_keys_str_mv | AT mahoneymartinc cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT rivardcheryl cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT kimmelheatherl cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT hammadhodat cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT sharmaeva cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT halenarmichaelj cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT sargentjim cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT cummingskmichael cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT niauraray cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT goniewiczmaciejl cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT bansaltraversmaansi cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT hatsukamidorothy cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT gaalemadiann cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT fonggeoffrey cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT gravelyshannon cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT christensencarolh cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT haskinsryan cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT silveiramarushkal cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT blancocarlos cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT comptonwilson cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT stantoncassandraa cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 AT hylandandrew cardiovascularoutcomesamongcombustibletobaccoandelectronicnicotinedeliverysystemendsusersinwaves1through5ofthepopulationassessmentoftobaccoandhealthpathstudy20132019 |